BriaCell Therapeutics Corp. (BCT.TO)
CAD 6.04
(-2.11%)
CAD 6.04
(-2.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 8.55 Million USD | -72.34% |
| 2023 | 30.94 Million USD | -4.05% |
| 2022 | 32.24 Million USD | 4022.54% |
| 2021 | 782.23 Thousand USD | -79.27% |
| 2020 | 3.77 Million CAD | 256.28% |
| 2019 | 1.05 Million CAD | -20.97% |
| 2018 | 1.33 Million CAD | 51.25% |
| 2017 | 885.9 Thousand CAD | 1723.19% |
| 2016 | 48.59 Thousand CAD | -58.53% |
| 2015 | 117.16 Thousand CAD | -93.62% |
| 2014 | 1.83 Million CAD | 2367.85% |
| 2013 | 74.46 Thousand CAD | -73.78% |
| 2012 | 283.94 Thousand CAD | -49.24% |
| 2011 | 559.42 Thousand CAD | 1819.0% |
| 2010 | 29.15 Thousand CAD | -54.58% |
| 2009 | 64.18 Thousand CAD | 310.34% |
| 2008 | 15.64 Thousand CAD | 63.19% |
| 2007 | 9584.94 CAD | -42.04% |
| 2006 | 16.53 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 20.54 Million USD | 27.61% |
| 2024 Q1 | 16.1 Million USD | -47.96% |
| 2024 Q3 | 12.43 Million USD | -39.48% |
| 2024 Q4 | 8.55 Million USD | -31.19% |
| 2023 Q4 | 30.94 Million USD | -13.12% |
| 2023 Q3 | 35.61 Million USD | 0.49% |
| 2023 Q2 | 35.44 Million USD | 26.06% |
| 2023 Q1 | 28.11 Million USD | -12.81% |
| 2023 FY | 30.94 Million USD | -4.05% |
| 2022 Q3 | 644.68 Thousand USD | -24.48% |
| 2022 Q2 | 853.63 Thousand USD | 11.65% |
| 2022 Q1 | 764.55 Thousand USD | -2.26% |
| 2022 FY | 32.24 Million USD | 4022.54% |
| 2022 Q4 | 32.24 Million USD | 4902.13% |
| 2021 Q2 | 4.08 Million CAD | 6.96% |
| 2021 FY | 782.23 Thousand USD | -79.27% |
| 2021 Q1 | 3.82 Million CAD | 1.31% |
| 2021 Q4 | 782.23 Thousand USD | -89.18% |
| 2021 Q3 | 7.22 Million CAD | 76.84% |
| 2020 Q2 | 2.73 Million CAD | 111.94% |
| 2020 Q4 | 3.77 Million CAD | 18.06% |
| 2020 FY | 3.77 Million CAD | 256.28% |
| 2020 Q1 | 1.29 Million CAD | 22.08% |
| 2020 Q3 | 3.19 Million CAD | 16.64% |
| 2019 Q3 | 555.44 Thousand CAD | -63.99% |
| 2019 Q1 | 1.04 Million CAD | -22.03% |
| 2019 FY | 1.05 Million CAD | -20.97% |
| 2019 Q4 | 1.05 Million CAD | 90.64% |
| 2019 Q2 | 1.54 Million CAD | 47.62% |
| 2018 Q3 | 1.36 Million CAD | 315.85% |
| 2018 FY | 1.33 Million CAD | 51.25% |
| 2018 Q4 | 1.33 Million CAD | -1.5% |
| 2018 Q2 | 327.13 Thousand CAD | -0.66% |
| 2018 Q1 | 329.29 Thousand CAD | -62.83% |
| 2017 Q1 | 32.89 Thousand CAD | -32.29% |
| 2017 Q4 | 885.9 Thousand CAD | 6301.97% |
| 2017 FY | 885.9 Thousand CAD | 1723.19% |
| 2017 Q3 | 13.83 Thousand CAD | 84.01% |
| 2017 Q2 | 7520.37 CAD | -77.14% |
| 2016 Q4 | 48.59 Thousand CAD | -37.18% |
| 2016 Q1 | 105.17 Thousand CAD | -10.24% |
| 2016 Q3 | 77.34 Thousand CAD | -4.23% |
| 2016 Q2 | 80.75 Thousand CAD | -23.21% |
| 2016 FY | 48.59 Thousand CAD | -58.53% |
| 2015 Q2 | 118.37 Thousand CAD | -94.32% |
| 2015 FY | 117.16 Thousand CAD | -93.62% |
| 2015 Q3 | 121.57 Thousand CAD | 2.7% |
| 2015 Q4 | 117.16 Thousand CAD | -3.62% |
| 2015 Q1 | 2.08 Million CAD | 13.48% |
| 2014 FY | 1.83 Million CAD | 2367.85% |
| 2014 Q4 | 1.83 Million CAD | 2214.2% |
| 2014 Q3 | 79.4 Thousand CAD | 0.32% |
| 2014 Q2 | 79.15 Thousand CAD | 6.98% |
| 2014 Q1 | 73.99 Thousand CAD | -0.63% |
| 2013 Q3 | 36 Thousand CAD | 25.35% |
| 2013 Q2 | 28.72 Thousand CAD | -75.25% |
| 2013 Q1 | 116.04 Thousand CAD | -59.13% |
| 2013 FY | 74.46 Thousand CAD | -73.78% |
| 2013 Q4 | 74.46 Thousand CAD | 106.82% |
| 2012 Q4 | 283.94 Thousand CAD | 235.93% |
| 2012 Q3 | 84.52 Thousand CAD | 134.45% |
| 2012 Q2 | 36.05 Thousand CAD | -89.91% |
| 2012 Q1 | 357.18 Thousand CAD | -36.15% |
| 2012 FY | 283.94 Thousand CAD | -49.24% |
| 2011 Q1 | 91.07 Thousand CAD | 212.4% |
| 2011 Q2 | 85.36 Thousand CAD | -6.27% |
| 2011 Q3 | 74.41 Thousand CAD | -12.82% |
| 2011 Q4 | 559.42 Thousand CAD | 651.74% |
| 2011 FY | 559.42 Thousand CAD | 1819.0% |
| 2010 Q1 | 28.29 Thousand CAD | -55.92% |
| 2010 Q3 | 40.4 Thousand CAD | 330.9% |
| 2010 Q2 | 9377.40 CAD | -66.86% |
| 2010 FY | 29.15 Thousand CAD | -54.58% |
| 2010 Q4 | 29.15 Thousand CAD | -27.85% |
| 2009 Q3 | 5573.56 CAD | -51.0% |
| 2009 Q4 | 64.18 Thousand CAD | 1051.61% |
| 2009 Q2 | 11.37 Thousand CAD | 289.04% |
| 2009 Q1 | 2923.86 CAD | -81.31% |
| 2009 FY | 64.18 Thousand CAD | 310.34% |
| 2008 FY | 15.64 Thousand CAD | 63.19% |
| 2008 Q4 | 15.64 Thousand CAD | 434.98% |
| 2008 Q3 | 2923.83 CAD | -38.53% |
| 2008 Q2 | 4756.69 CAD | -63.76% |
| 2008 Q1 | 13.12 Thousand CAD | 36.93% |
| 2007 Q4 | 9584.94 CAD | 375.04% |
| 2007 Q2 | 256.02 CAD | -97.66% |
| 2007 Q3 | 2017.69 CAD | 688.1% |
| 2007 Q1 | 10.94 Thousand CAD | 0.0% |
| 2007 FY | 9584.94 CAD | -42.04% |
| 2006 FY | 16.53 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | 31.075% |
| Eupraxia Pharmaceuticals Inc. | 25.54 Million CAD | 66.503% |
| Helix BioPharma Corp. | 1.57 Million CAD | -441.937% |
| Microbix Biosystems Inc. | 11.02 Million CAD | 22.409% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | 38.627% |
| Satellos Bioscience Inc. | 3.62 Million CAD | -136.126% |
| Oncolytics Biotech Inc. | 11.25 Million CAD | 23.983% |
| Sernova Corp. | 9.59 Million CAD | 10.791% |